BCRX Biocryst Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: BCRX
Price (delayed)
$8.35
Market cap
$1.75B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.18
Enterprise value
$2.4B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of
Highlights
The net income has surged by 76% year-on-year and by 33% since the previous quarter
BCRX's EPS has soared by 75% YoY and by 31% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 28% QoQ and by 25% YoY
Key stats
What are the main financial stats of BCRX
Market
Valuations
Earnings
Shares outstanding
209.92M
Market cap
$1.75B
Enterprise value
$2.4B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
3.14
EV/EBIT
38.66
EV/EBITDA
37.88
EV/Sales
4.31
Revenue
$557.51M
Gross profit
$540.78M
Operating income
$54.2M
Net income
-$35.71M
EBIT
$62.16M
EBITDA
$63.44M
Free cash flow
$15.76M
Per share
Balance sheet
Liquidity
EPS
-$0.18
EPS diluted
-$0.18
Free cash flow per share
$0.08
Book value per share
-$2.01
Revenue per share
$2.66
TBVPS
$2.18
Total assets
$457.19M
Total liabilities
$878.78M
Debt
$738.92M
Equity
-$421.59M
Working capital
$221.3M
Debt to equity
-1.75
Current ratio
2.25
Quick ratio
1.99
Net debt/EBITDA
10.25
Margins
Efficiency
Dividend
EBITDA margin
11.4%
Gross margin
97%
Net margin
-6.4%
Operating margin
9.7%
Return on assets
-7.4%
Return on equity
N/A
Return on invested capital
6%
Return on capital employed
22.2%
Return on sales
11.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCRX stock price
How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
-2.91%
1 week
2.58%
1 month
-4.68%
1 year
12.23%
YTD
11.04%
QTD
-6.81%
Financial performance
How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$557.51M
Gross profit
$540.78M
Operating income
$54.2M
Net income
-$35.71M
Gross margin
97%
Net margin
-6.4%
BCRX's operating income has soared by 190% YoY and by 63% QoQ
The operating margin has soared by 161% YoY and by 47% from the previous quarter
BCRX's net margin has soared by 83% YoY and by 40% QoQ
The net income has surged by 76% year-on-year and by 33% since the previous quarter
Price vs fundamentals
How does BCRX's price correlate with its fundamentals
Growth
What is Biocryst Pharmaceuticals's growth rate over time
Valuation
What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
3.14
EV/EBIT
38.66
EV/EBITDA
37.88
EV/Sales
4.31
BCRX's EPS has soared by 75% YoY and by 31% from the previous quarter
BCRX's equity is up by 11% year-on-year and by 7% since the previous quarter
The P/S is 78% lower than the 5-year quarterly average of 14.6 and 8% lower than the last 4 quarters average of 3.4
BCRX's revenue is up by 46% YoY and by 11% QoQ
Efficiency
How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS has soared by 193% YoY and by 21% from the previous quarter
The company's return on assets has surged by 75% YoY and by 33% QoQ
The ROIC rose by 40% QoQ
Dividends
What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCRX.
Financial health
How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 48% lower than its total liabilities
Biocryst Pharmaceuticals's quick ratio has decreased by 28% QoQ and by 25% YoY
Biocryst Pharmaceuticals's current ratio has decreased by 23% from the previous quarter and by 20% YoY
BCRX's debt is down by 13% YoY and by 11% QoQ
BCRX's equity is up by 11% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.